Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 1996-2003

  Velasquez, William S ^a   Lew, Danika ^a   Grogan, Thomas M ^a   Spiridonidis, C Harris ^a   Balcerzak, Stanley P ^a   Dakhil, Shaker R ^a   Miller, Thomas P ^a   Lanier, Keith S ^a   Chapman, Robert A ^a   Fisher, Richard I ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME; ADULT; AGED; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; VIDARABINE;

EID: 0038011940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.047     Document Type: Article

References (31)

1. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas summary and description for a working formulation for clinical usage. Cancer 49:2112-2135, 1982
2. Horning SJ: Natural history and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993 (suppl)
3. Decandin D, Lepage E, Brousse N, et al: Low-grade stage III-IV follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients-A study of the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 17:2499-2505, 1999
4. Harris NL, Jaffee ES, Stein H, et al: A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
5. Pileri SA, Milani M, Fraternali-Orcioni G, et al: From the R.E.A.L. Classification to the upcoming WHO scheme: A step toward universal categorization of lymphoma entities? Ann Oncol 9:607-612, 1998
6. Dana BW, Dahlberg S, Nathwani B, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
7. Jones SE, Grozea PN, Miller TP, et al: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A Southwest Oncology Group study. J Clin Oncol 3:1318-1324, 1985
8. Fisher RI, Dana BW, LeBlanc M, et al: Interferon alpha consolidation after intensive chemotherapy did not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 18:2010-2016, 2000
9. Smalley RV, Weller E, Hawkins MJ, et al: Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha 2a) plus an anthracycline-based induction regimen. Leukemia 15:1118-1122, 2001
10. Arranz R, Garcia-Alfonso P, Sobrino P, et al: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization. J Clin Oncol 16:1538-1546, 1998
11. McLaughlin P, Hagemeister FB, Swan F, et al: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-579, 1994
12. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone, and dexamelhasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
13. Anaisse EJ, Kontoyiannis DP, O'Brien S, et al: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559-566, 1998
14. Keating MJ, Smith TL, Lerner S, et al: Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma 37:71-85, 2000
15. Kaplan ES, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-480, 1958
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
17. Swan F, Velasquez WS, Tucker S, et al: A new serologic staging system for large-cell lymphomas based on initial beta-2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518-1527, 1989
18. Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992
19. Hochster HS, Kim KM, Green MD, et al: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
20. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
21. Tsimberidou AM, McLaughlin P, Younes A, et al: Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100:4351-4357, 2002
22. McLaughlin P, Hagemeister FB, Rodriquez MA, et al: Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27:37-41, 2000 (suppl)
23. Coiffier B, Neidhardt-Berard EM, Tilly H, et al: Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study-Groupe d'Etudes des Lymphomes l'Adulte. Ann Oncol 10:1191-1197, 1999
24. Hagenbeek A, Eghbali H, Monfardini S, et al: Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma: Preliminary results from a prospective, randomized phase III clinical trial in 381 patients-American Society of Hematology meeting. Blood 92:315a, 1998 (abstr 1294)
25. Zinzani PL, Magagnoli M, Bendandi M, et al: Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol 11:363-365, 2000
26. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: The clinical significance of molecular response in indolent follicular lymphoma. Blood 91:2955-2960, 1998
27. Hochster HS, Oken MM, Winter JN, et al: Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up-A report from the Eastern Cooperative Oncology Group. J Clin Oncol 18:987-994, 2000
28. Lazzarino M, Orlandi E, Montillo M, et al: Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 10:59-64, 1999
29. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
30. Longo DL, Duffey PL, Gribben JG, et al: Combination chemotherapy followed by an immunotoxin (anti B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study. Cancer J 6:146-150, 2000
31. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97:404-409, 2001